Celanese debuts controlled-release excipients

Celanese has unveiled VitalDose, an excipient for controlled-release drugs. The ingredients allow drugmakers to customize API release properties.

VitalDose is intended for transdermal, subcutaneous implant, and mucosal insert dosage forms, the company says. The specialty materials maker is targeting the opportunity it sees in new routes of administration for existing drugs as a means of thwarting generics competition. Enhanced bioavailability of poorly soluble drugs is another application.

The new excipients are based on ethylene vinyl acetate polymers.

- here's the Celanese announcement

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.